191 results about "Recurrence risk" patented technology

The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.

The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.

The invention discloses a clinical cerebral infarction patient recurrence risk early warning scoring visual model system. The system comprises an input module, an analysis module and a result output module. The invention also discloses an evaluation method of the clinical cerebral infarction patient recurrence risk early warning scoring visual model system. A clinical cerebral infarction patient recurrence risk evaluation nomogram is concise, popular and easy to understand and convenient for clinicians and patients to operate, and a current cerebral infarction recurrence risk of the patients is predicted. And meanwhile, high-risk, medium-risk and low-risk groups can be clearly distinguished according to patient risk scores calculated by a risk scoring formula in the model so that the clinicians are assisted to formulate an efficient treatment scheme. In the invention, a doctor and the patient are guided to evaluate early warning scores of the clinical cerebral infarction patient recurrence risk in combination with a statistical method, and patient data acquisition is verified through a corresponding mathematical statistical method so that the doctor and the patient can quickly grasp the clinical cerebral infarction patient recurrence risk and provide early warning information.

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

The invention discloses a multi-antibody detection kit used in postoperative recurrence risk assessment after a resection operation is performed on a primary hepatocellular carcinoma patient. The kit comprises 8 immunohistochemical antibodies used for paraffin sections. The invention also discloses a method for determining postoperative recurrence risk of a liver cancer patient by using the kit. The prediction effect provided by the invention is superior to an existing clinical index. The kit and the method provided by the invention have characteristics of objective, convenient, direct, and repeatable. The kit can be used in the predictions of recurrence and death after clinical liver cancer resection operations. The kit assists in screening liver cancer patients with high postoperative recurrence risk. Therefore, appropriate auxiliary treatments can be directed, recurrence can be effectively reduced, and patient survival time can be prolonged.

The invention relates to the field of medical biological detection, in particular to a detection reagent or a kit for evaluating liver cancer transfer and recurrence risks after orthotopic liver transplantation through combination of AFP (alpha fetoprotein) detection and iFISH-CTC (circulating tumor cells) detection, and a detection method of the detection reagent or the kit. The liver cancer transfer and recurrence risks after the orthotopic liver transplantation are evaluated through detection of the content of AFP and the number of CTC, so that a new measure is provided for detection of liver cancer transfer and recurrence after the orthotopic liver transplantation so as to start clinical intervention as early as possible, worsening of patients' conditions is prevented, and prognosis of patients is improved.

The invention relates to a method for performing prognosis condition grouping on a hepatocellular carcinoma patient who has single tumor and is about to be subjected to or is already subjected to orthotopic liver transplantation. The method comprises the steps of (1) obtaining a sample from general samples after transhepatic biopsy before transplantation or liver transplantation, and detecting CK19 and GPC3 expression conditions of tumor cells in the hepatocellular carcinoma tissue sample of the patient; (2) detecting and recording a maximum diameter of the tumor of the patient; (3) detecting and recording a serum alpha-fetoprotein level of the patient; and (4) based on a pathological section, observing whether microvascular invasion exists or not. Recurrent risks are scored according to beta coefficients of four factors in COX regression analysis; scores in items are subjected to addition; a recurrent risk group with a total score less than or equal to 4 is determined as a low recurrent risk group; a recurrent risk group with a total score equal to 5-7 is determined as a medium recurrent risk group; and a current risk group with a total score more than or equal to 8 is determined as a high recurrent risk group. Through the method, an effective auxiliary information value can be provided for a doctor and the patient; and tumor recurrence or transfer is closely monitored, so that health conditions can be discovered within the shortest time, the doctor and the patient are effectively prompted, and people are reminded to timely examine body conditions.

The invention discloses a prognostic marker gene for predicting recurrence of II-stage colorectal cancer and application. The invention provides a model for predicting the recurrence risk of a patientaccording to gene expression information of tumors of II-stage colorectal cancer patients. The AUC value of the model for predicting the five-year recurrence risk of the II-stage colorectal cancer patients is 0.993, and patients with high recurrence risk and patients with low recurrence risk can be remarkably separated in a test set. For the establishment and selection of the model, a random survival forest model is used, variable screening is carried out according to the minimum depth value of the maximum sub-tree where variables are located, and an important variables are selected to reestablish the model, so that the variable dimension of the model is greatly reduced. After the patients are divided into a high recurrence risk group and a low recurrence risk group by using the random survival forest model in a test set, no-recurrence lifetimes of the patients of the two groups have significant difference.

The invention provides a recurrence predicting reagent kit for liver cancer liver transplantation postoperation, which is characterized in that the reagent kit uses two SNPrs rs894151 and rs12438080 in a plasma circulation DNA as detection sites, uses upstream sequences and downstream sequences of the rs894151 and the rs12438080 as amplimers, and uses fluorescent probes as genotyping probes. The invention can evaluate the recurrence risk of the liver transplantation operation carried out by liver cancer patients before the operation, and in addition, the invention uses peripheral blood as detection samples, and has the characteristics of high speed, accuracy, convenience, simplicity, easy popularization and application and the like. The invention can be used for sieving the clinical liver cancer liver transplantation patients, can guide the auxiliary treatment after the liver cancer liver transplantation operation, and can reduce the postoperation recurrence rate of high-risk patients, so the prognosis of the liver cancer liver transplantation is improved, and the limited donor livers can be effectively utilized. The reagent kit has important clinical significance to the prognosis judgment on patients exceeding the Milan standard.